MDM2 and glioblastoma: Similarly, glioblastoma with high MDM2 levels exhibits greater resistance to therapy and reduced survival outcomes (Sato et al., 2011), while breast cancer frequently displays elevated MDM2 expression, correlating with poor clinical progression (Turbin et al., 2006; Yao et al., 2024).